secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2026-07-09T20:08:54+00:00
Accession:  0001437749-26-023199
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell Q2 product sales rise 11.5% to $7.2M; domestic sales up 27.7% YoY
--------------------------------------------------------------------------

- Q2 2026 total product sales $7.2M vs $6.4M in Q2 2025, an 11.5% increase.
- Domestic sales grew 27.7% to $6.2M; international sales fell 38.9% to $1.0M.
- First-half 2026 product sales $17.5M, up 20.9% from $14.5M in H1 2025.
- Tri-Shield sales up 8.3% to $4.9M; Dual-Force and other sales up 19.1% to $2.3M in Q2.
- Results are preliminary and unaudited; full Q2 earnings call scheduled for Aug 14, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/0001437749-26-023199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000143774926023199/iccc20260708_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-023199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer